This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Enbrel | |
|---|---|
| Name | Enbrel |
| Tradename | Enbrel |
| Generic | etanercept |
| Routes | Subcutaneous injection, intravenous infusion (investigational) |
| Class | Tumor necrosis factor inhibitor |
Enbrel Enbrel is a biologic medicine used to treat several autoimmune and inflammatory conditions. It functions as a tumor necrosis factor (TNF) blocker prescribed by specialists in rheumatology, dermatology, and gastroenterology, and is produced and marketed by a major pharmaceutical company. Enbrel's introduction altered treatment paradigms for chronic diseases and generated significant clinical, regulatory, and commercial discussion.
Enbrel is indicated for moderate to severe Rheumatoid arthritis, active Psoriatic arthritis, plaque psoriasis, and pediatric Juvenile idiopathic arthritis; it has been used off-label or studied for Ankylosing spondylitis, Inflammatory bowel disease, and other immune-mediated disorders. Clinical trials compared Enbrel to disease-modifying antirheumatic drugs studied by groups from National Institutes of Health, Food and Drug Administration, and academic centers like Mayo Clinic and Johns Hopkins Hospital. Treatment guidelines from organizations such as the American College of Rheumatology, European League Against Rheumatism, and British Society for Rheumatology reference Enbrel among biologic options. Specialty societies including American Academy of Dermatology and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition have issued position statements or trial data involving Enbrel.
Enbrel is a fusion protein composed of the extracellular ligand-binding portion of the human Tumor necrosis factor receptor 2 linked to the Fc portion of human Immunoglobulin G1. It binds soluble and membrane-bound Tumor necrosis factor to inhibit downstream signaling cascades characterized by cytokines studied in laboratories like Howard Hughes Medical Institute-funded groups and described in reviews from Lancet and New England Journal of Medicine. Mechanistic studies published by researchers affiliated with Harvard Medical School, Stanford University, and University of California, San Francisco examined its effects on synovial inflammation, T cell activation, and markers tracked in trials run at institutions such as Massachusetts General Hospital. Enbrel’s pharmacokinetics, including absorption after subcutaneous injection and half-life modulation by neonatal Fc receptor pathways elucidated at Scripps Research, influence dosing regimens.
Typical adult dosing regimens used in trials from Duke University and Cleveland Clinic include weekly subcutaneous injections of a fixed dose or twice-weekly induction dosing for specific indications; pediatric dosing is weight-based per studies from Children's Hospital of Philadelphia and Great Ormond Street Hospital. Administration training is provided by specialty clinics associated with Kaiser Permanente and patient education programs run by patient advocacy groups such as the Arthritis Foundation and National Psoriasis Foundation. Storage and handling guidance aligns with standards from World Health Organization cold chain recommendations and pharmacy practices taught at schools like University of Oxford and University of Cambridge.
Adverse effects observed in clinical trials and postmarketing surveillance reported to European Medicines Agency and Centers for Disease Control and Prevention include injection site reactions, infections, and rare reports of demyelinating disorders. Serious infections involving organisms documented by teams at Centers for Disease Control and Prevention and World Health Organization required vigilance for tuberculosis reactivation screened by protocols from World Health Organization and Centers for Disease Control and Prevention. Observational studies published by Johns Hopkins Hospital and Brigham and Women's Hospital examined associations with malignancy and cardiovascular outcomes, debated in editorials in Journal of the American Medical Association and BMJ. Pharmacovigilance databases managed by European Medicines Agency and Food and Drug Administration continue to monitor long-term safety.
Enbrel is contraindicated in patients with active severe infections identified in clinical guidance from National Institute for Health and Care Excellence and American Academy of Allergy, Asthma & Immunology. Caution is advised in patients with a history of demyelinating disease noted by neurologists at Mayo Clinic and oncologists at Memorial Sloan Kettering Cancer Center when weighing risks versus benefits. Screening recommendations for latent tuberculosis follow algorithms from World Health Organization and Centers for Disease Control and Prevention. Vaccination guidance from Advisory Committee on Immunization Practices and European Centre for Disease Prevention and Control informs live vaccine avoidance during therapy.
Enbrel was developed through collaborations between biotechnology firms and academic labs, emerging from recombinant DNA and monoclonal antibody technologies advanced by scientists at Genentech, Amgen, and university groups at University of California, Berkeley and Massachusetts Institute of Technology. Regulatory approvals began in the late 1990s following pivotal trials conducted at centers including Hospital for Special Surgery and University College London Hospital. Its development and commercialization involved notable industry entities such as Immunex and Wyeth and later partnerships and corporate transactions with Amgen and Pfizer that shaped access and marketing strategies discussed in analyses by The New York Times and Financial Times.
Enbrel is approved and marketed in many countries after assessment by regulators like the Food and Drug Administration, European Medicines Agency, and national agencies including Health Canada and the Therapeutic Goods Administration. Biosimilar competition and patent litigation involved firms such as Sandoz, Samsung Bioepis, and Pfizer, with court decisions reported in outlets like Reuters and Bloomberg. Reimbursement decisions by payers such as Medicare, NHS England, and private insurers influence prescribing, with patient assistance programs run by foundations including the Arthritis Foundation and international NGOs.
Category:Biopharmaceuticals